Ergometrine 500micrograms/1ml solution for injection ampoules
Requires a prescription from a doctor or prescriber
An ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ergometrine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ergometrine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Ergometrine on the MHRA register
Ergometrine 500micrograms/1ml solution for injection ampoules
WHO defined daily dose (DDD)
200 microgram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(2)
Intrapartum care (NG235)
Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 20 studies.
Reviews & meta-analyses: 2 · Randomised trials: 1 · 2022–2026
Showing all 20 studies, sorted by most relevant.
Elsayed Ibrahim, Mohammad Hassan, Abdul-Rhman Abdeltwab
Al-Azhar International Medical Journal, 2026
Background: Blood loss of 500 milliliters or more from the vaginal tract following delivery is referred to as postpartum hemorrhage. Even within the usual range, a parturient with severe anaemia may die from hemorrhage. Aim: For the purpose of contrasting the safety and effectiveness of intravenous methyl ergometrine with oral misoprostol in preventing postpartum hemorrhage in women having a normal vaginal birth.Subjects and methods: Over the course of a year, 140 patients from the Obstetrics and Gynecology Department at Al-Azhar University Hospitals in Cairo, Egypt, participated in this prospective randomized controlled trial.Results: The misoprostol group had a significantly higher proportion of primigravid patients (54.3% vs 35.7%, p=0.021), which is clinically relevant as primigravidity is associated with increased risk of PHH and different uterine contractility patterns. The incidence of blood loss>500mL was similar between groups (17.1% vs 21.4%, p=0.33), as was severe hemorrhage>1000mL (1.4% vs 1.4%, p=0.75).Conclusion: The 400μg sublingual misoprostol is as effective as 200μg intravenous methylergonovine for preventing PHH, with comparable safety profiles. The equivalent efficacy, combined with misoprostol's practical advantages in terms of stability, route of administration, and cost, supports its use as a viable alternative to methylergonovine for PHH prevention.
Abstract licence: CC BY-SA
Martins IM, Dinis-Oliveira RJ, Costa JG, et al.
2025
- Ergot Alkaloids
- Food Contamination
- Psychotropic Drugs
Food contamination has been a major health issue since the beginning of human existence. Some food contaminants trigger important psychological manifestations, such as delirium, hallucinations, and psychosis, which may cause distress, aggravate pre-existing conditions, and dangerously interact with certain medications. Exposure to psychoactive food contaminants can ultimately lead to severe health problems or even death. As such, it is important to further study these substances to prevent contamination and identify and treat intoxications. Among these substances, three classes of food contaminants are addressed herein due to their toxicological relevance: (i) ergot alkaloids (ergotamine and ergometrine), (ii) tropane alkaloids (atropine, hyoscyamine, and scopolamine), and (iii) opium alkaloids (codeine and morphine). An historical perspective relative to each contaminant is briefly described in this review, as well as the dietary sources and key chemical properties. Guidance values and analytical methods that allow the detection and quantification of these toxic agents are also provided. In addition, relevant toxicokinetic and toxicodynamic aspects are summarized. Finally, for each xenobiotic, registered intoxication cases, from epidemics and outbreaks to case reports, are described, as well as the detection of contaminants in screening procedures. Overall, this review reinforces that dietary exposure to psychoactive contaminants constitutes a toxicological issue that should be duly considered.
Abstract licence: CC BY
Jagruti Kirdant, I. Roy, Barnali Bhuyan, et al.
Indian Journal of Obstetrics and Gynecology Research, 2022
: Drug induced vasculitis is an inflammation of blood vessels caused by use of various drugs like ergometrine, inotropes. The purpose of this review is to highlight the importance of ergotism as a cause of peripheral vascular ischemia and analyze the changes associated with this condition. Mrs. XX, 21 year old, P2L1 presented with history of normal delivery in PHC eight days back with complaints of breathlessness, fever and bluish grey discoloration of both lower extremities since her delivery. There was history of severe postpartum hemorrhage post delivery in the PHC and was medically managed with ergometrine and other oxytocics. On examination, patient had pallor, temperature and tachycardia. Dorsalis pedis pulsation was palpable in both lower limbs. Thorough workup was done which revealed hemoglobin 6.9 gm% and high total count. Doppler study of both lower limbs and ECHO were normal. Patient was managed conservatively after which she improved symptomatically but there was no improvement in the line of demarcation in both lower limbs. Due to financial constraints, patient decided to shift to government setup for further management. Ergometrine is recommended by ACOG and RCOG for use in the medical management of atonic postpartum hemorrhage after oxytocics. Ergometrine has a vasoconstrictive effect which causes progressive vasospasm leading to peripheral ischemia and gangrene which may lead to amputation of the limbs. Hence, management of postpartum hemorrhage with minimum effective dose of ergometrine should be emphasized and use of other oxytocics should be encouraged to prevent such major complications.
Abstract licence: CC BY-NC-SA
S. Höfs, Valerie Jaut, R. Schneider
Talanta, 2023
- Ergonovine
- Ergot Alkaloids
- Flour
A certain group of mycotoxins, the ergot alkaloids, has caused countless deaths throughout human history. They are found in rye and other cereals and ingesting contaminated foods can cause serious health problems. To identify contaminated food exceeding the legal limits for ergot alkaloids, a portable and cost-effective test system is of great interest to the food industry. Rapid analysis can be achieved by screening for a marker compound, for which we chose ergometrine. We developed a magnetic bead-based immunoassay for ergometrine with amperometric detection in a flow injection system using a handheld potentiostat and a smartphone. With this assay a limit of detection of 3 nM (1 μg L−1) was achieved. In spiked rye flour, ergometrine levels from 25 to 250 μg kg−1 could be quantified. All results could be verified by optical detection. The developed assay offers great promise to meet the demand for on-site ergometrine detection in the food industry.
Abstract licence: CC BY-NC-ND
Neumann J, Dhein S, Kirchhefer U, et al.
2024
Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely, 5-HT 2A -serotonin receptors in the brain. However, a close study reveals that they also act on the heart, possibly increasing the force of contraction and beating rate and may lead to arrhythmias. Here, we will review the inotropic and chronotropic actions of bufotenin, psilocin, psilocybin, lysergic acid diethylamide (LSD), ergotamine, ergometrine, N,N-dimethyltryptamine, and 5-methoxy-N,N-dimethyltryptamine in the human heart.
Abstract licence: CC BY
Hui Xue, Weijing Wang
American journal of translational research, 2023
Hannes Jacob, Pauline Braekow, B. Hofmann, et al.
Naunyn-Schmiedeberg's Archives of Pharmacology, 2023
- Atrial Fibrillation
- Serotonin
- Heart Atria
Abstract Ergometrine (6a R ,9 R )- N -(( S )-1-hydroxypropan-2-yl)-7-methyl-4,6,6a,7,8,9-hexa-hydro-indolo-[4,3- fg ]chinolin-9-carboxamide or lysergide acid β-ethanolamide or ergonovine) activates several types of serotonin and histamine receptors in the animal heart. We thus examined whether ergometrine can activate human serotonin 5-HT 4 receptors (h5-HT 4 R) and/or human histamine H 2 receptors (hH 2 R) in the heart of transgenic mice and/or in the human isolated atrium. Force of contraction or beating rates were studied in electrically stimulated left atrial or spontaneously beating right atrial preparations or spontaneously beating isolated retrogradely perfused hearts (Langendorff setup) of mice with cardiac specific overexpression of the h5-HT 4 R (5-HT 4 -TG) or of mice with cardiac specific overexpression of the hH 2 R (H 2 -TG) or in electrically stimulated human right atrial preparations obtained during cardiac surgery. Western blots to assess phospholamban (PLB) phosphorylation on serine 16 were performed. Ergometrine exerted concentration- and time-dependent positive inotropic effects and positive chronotropic effects in atrial preparations starting at 0.3 µM and reaching a plateau at 10 µM in H 2 -TGs ( n = 7). This was accompanied by an increase in PLB phosphorylation at serine 16. Ergometrine up 10 µM failed to increase force of contraction in left atrial preparations from 5-HT 4 -TGs ( n = 5). Ten micrometer ergometrine increased the force of contraction in isolated retrogradely perfused spontaneously beating heart preparations (Langendorff setup) from H 2 -TG but not 5-HT 4 -TG. In the presence of the phosphodiesterase inhibitor cilostamide (1 µM), ergometrine at 10 µM exerted positive inotropic effects in isolated electrically stimulated human right atrial preparations, obtained during cardiac surgery, and these effects were eliminated by 10 µM of the H 2 R antagonist cimetidine but not by 10 µM of the 5-HT 4 R antagonist tropisetron. Furthermore, ergometrine showed binding to human histamine H 2 receptors (at 100 µM and 1 mM) using HEK cells in a recombinant expression system (p K i < 4.5, n = 3). In conclusion, we suggest that ergometrine is an agonist at cardiac human H 2 Rs.
Abstract licence: CC BY
Dube R, Kar SS, Satapathy S, et al.
2025
Background: There is a need for signs that will help the midwives or the health care providers attending deliveries to prevent the patient from going into hypovolemic shock, especially when immediate testing is not possible. The study aims to find the correlation between the clinical symptoms and blood loss in women with postpartum hemorrhage. Methods: It is a descriptive observational study conducted at the Department of Obstetrics and Gynecology, Maternity Hospitals. Women treated with either Misoprostol or Ergometrine during delivery were included in the study. Data were collected for Packed Cell Volume (PCV), Hemoglobin (Hb%), etc. ; other investigations include general clinical condition, presence or absence of PPH, and amount of blood loss using laboratory reports. Results: The study has reported clinical findings and blood loss to identify the correlation between them. Only 4% of women suffered blood loss of more than 500 mL, i.e., postpartum hemorrhage (PPH) occurred among them. The change in Hb% among the majority of the women was ranging between 0–0.5 gm% (71.5%). Most cases (72.72%) had tachycardia followed by palpitation (10.90%). Blood loss exceeding 1500 mL was correlated with hypotension, restlessness, and oliguria. Conclusions: Extra vigilance is needed to identify women at risk and facilitate early intervention and treatment of PPH.
Abstract licence: CC BY
Louise Makarious, P. Shetty, D. Tanous, et al.
BMJ Case Reports, 2025
- Cesarean Section
- Ergonovine
- Oxytocics
A. Radhakrishna, C. Burke, Patrick Barry, et al.
European Heart Journal. Case Reports, 2025
Background: Ergometrine is part of the current guideline-directed management of post-partum haemorrhage (PPH). However, it is also a potent vasoconstrictor capable of causing significant coronary artery vasospasm in susceptible individuals. Case summary: A 31-year-old primigravida suffered from post-partum haemorrhagic shock and disseminated intravascular coagulation following vaginal delivery. She was urgently resuscitated with intravenous fluids and blood products. Intramuscular ergometrine was administered, and surgery was required due to retained placenta. Two days later upon extubation, she demonstrated symptoms of speech apraxia. Brain magnetic resonance imaging (MRI) revealed extensive cerebral and cerebellar infarction with subcortical sparring. Her electrocardiogram showed diffuse T-wave inversions, and a high-sensitivity troponin-I peaked at 37 000 ng/L. Echocardiography showed severe left ventricular (LV) failure, apical akinesia, and thrombi formation. One week later, she suffered a middle cerebral artery stroke causing aphasia and right-sided hemiparesis, necessitating emergency thrombectomy. Cardiovascular MRI showed moderate LV systolic impairment and focal apical infarction. Coronary angiography was unremarkable. The most likely unifying diagnosis was severe ergotamine-induced coronary vasospasm causing acute myocardial infarction in the setting of life-threatening PPH. Following three weeks of multi-disciplinary care, her speech and motor abilities improved. She was discharged on long-acting nitrates, oral anticoagulation, and heart failure therapy with close outpatient monitoring. Subsequent echocardiograms showed marked improvement in LV ejection fraction (45%-50%). Discussion: This case highlights the potential life-threatening complications of ergometrine and the importance of recognizing pregnancy-associated myocardial infarction as a significant cause of maternal morbidity and mortality. The cardio-obstetrics team plays a pivotal role in improving patient outcomes.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
30 found
Half-life
10 minutes
Mechanism
Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions.
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
10 minutes
Metabolism
Elimination
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1299 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
ATC G02AB03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ergometrine
Additional database identifiers
Drugs Product Database (DPD)
9366
ChemSpider
391970
BindingDB
50390991
ZINC
ZINC000053174604
HUGO Gene Nomenclature Committee (HGNC)
HGNC:277
GenAtlas
ADRA1A
GeneCards
ADRA1A
GenBank Gene Database
D25235
GenBank Protein Database
433201
Guide to Pharmacology
22
UniProt Accession
ADA1A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3023
GenAtlas
DRD2
GeneCards
DRD2
GenBank Gene Database
M30625
GenBank Protein Database
181432
Guide to Pharmacology
215
UniProt Accession
DRD2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q424508), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.